Marsdenia tenacissima extract induces G0/G1 cell cycle arrest in human esophageal carcinoma cells by inhibiting mitogen-activated protein kinase (MAPK) signaling pathway

Chinese Journal of Natural Medicines

Volumn 13, Issue 6, 2015, Pages 428-437

  Fan, Wei ^a   Sun, Li ^a   Zhou, Jing Qian ^a   Zhang, Cang ^b   Qin, Song ^b   Tang, Ying ^b   Liu, Yang ^b   Lin, Sen Sen ^a   Yuan, Sheng Tao ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Nanjing Sanhome Pharmaceutical Co Ltd   (China)

Author keywords

Cell cycle arrest; Human esophageal cancer; Marsdenia tenacissima extract; Mitogen activated protein kinase signaling pathway

Indexed keywords

11ALPHA 0 2 METHYLBUTYRYL 12BETA O ACETYLTENACIGENIN B; 11ALPHA O TIGLOYL 12BETA O ACETYLTENACIGENIN B; 17BETA TENACIGENIN B; BROXURIDINE; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E1; CYCLINE; MARSDENIA TENACISSIMA EXTRACT; MARSDENOSIDE I; MARSECTOBISOSE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; REGULATOR PROTEIN; RETINOBLASTOMA PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TENACIGENIN A; TENACIGENIN B; TENACIGENOSIDE A; TENACISSOSIDE H; UNCLASSIFIED DRUG; HERBACEOUS AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRDU ASSAY; CANCER CELL LINE; CARCINOMA CELL; CELL CYCLE REGULATION; CELL GROWTH; CELL PROLIFERATION; CONDURANGO; CONTROLLED STUDY; CYTOTOXICITY; DRUG DETERMINATION; ENZYME INHIBITION; ESOPHAGUS CARCINOMA; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC50; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; MARSDENIA TENACISSIMA; MEDICINAL PLANT; MTT ASSAY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; APOPTOSIS; CARCINOMA; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; ESOPHAGEAL NEOPLASMS; METABOLISM; PATHOPHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DRUGS, CHINESE HERBAL; ESOPHAGEAL NEOPLASMS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MAP KINASE SIGNALING SYSTEM; MARSDENIA;

EID: 84931087119     PISSN: 20956975     EISSN: 18755364     Source Type: Journal    
DOI: 10.1016/S1875-5364(15)30036-4     Document Type: Article

References (49)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin 2011, 61(2):69-90.
2. Korn WM Prevention and management of early esophageal cancer [J]. Curr Treat Options Oncol 2004, 5(5):405-416.
3. Hamamoto Y, Kitagawa Y Current perspective of treatment for advanced esophageal squamous cell carcinoma [J]. Nihon Shokakibyo Gakkai Zasshi 2014, 111(2):253-259.
4. Karakas E, Oetzmann von Sochaczewski C, Haist T, et al. Limitations of surgery for cancer of the upper gastrointestinal tract [J]. Chirurg 2014, 85(3):186-191.
5. Tsukao Y, Yamazaki M, Miyazaki Y, et al. Complete response in a case of advanced esophageal cancer infiltrating into the main bronchus treated by chemoradiation therapy [J]. Gan To Kagaku Ryoho 2013, 40(12):2124-2126.
6. Woodall CE, Li Y, Liu QH, et al. Chemoprevention of metaplasia initiation and carcinogenic progression to esophageal adenocarcinoma by resveratrol supplementation [J]. Anticancer Drugs 2009, 20(6):437-443.
7. Ku GY, Ilson DH Adjuvant (postoperative) therapy for esophageal cancer [J]. Thorac Surg Clin 2013, 23(4):525-533.
8. Tanabe S, Shirakawa Y, Maeda N, et al. Current status of neoadjuvant chemotherapy for advanced esophageal cancer [J]. Gan To Kagaku Ryoho 2013, 40(12):1612-1624.
9. Wu F, Li H, Jin L, et al. Deer antler base as a traditional Chinese medicine: a review of its traditional uses, chemistry and pharmacology [J]. J Ethnopharmacol 2013, 145(2):403-415.
10. Wang Y, Deng L, Zhong H, et al. Natural plant extract tubeimoside I promotes apoptosis-mediated cell death in cultured human hepatoma (HepG2) cells [J]. Biol Pharm Bull 2011, 34(6):831-838.
11. Sun L, Lin SS, Zhao RP, et al. The saponin monomer of Dwarf Lilyturf tuber, DT-13, reduces human breast cancer cell adhesion and migration during hypoxia via regulation of tissue factor [J]. Biol Pharm Bull 2010, 33(7):1192-1198.
12. Gu Y, Scheuer C, Feng D, et al. Inhibition of angiogenesis: a novel antitumor mechanism of the herbal compound arctigenin [J]. Anticancer Drugs 2013, 24(8):781-791.
13. Han SY, Zhao MB, Zhuang GB, et al. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells [J]. Lung Cancer 2012, 75(1):30-37.
14. Xueyuan JX Zhongyao Dacidian [Encyclopedia of Chinese Materia Medica] [M] 1977, Shanghai Science and Technology Press, Shanghai.
15. Ministry of Public Health of China. Drug Quality Standard [S]. WS-10630(2D-6030)-2002-2-011Z.
16. Li K, Zou HW Clinical observation of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer [J]. Chin J Cancer Prev Treat 2007, 14:1272-1273.
17. Wang WY, Zhou Y, Zhang XJ, et al. A random study of Xiao- Ai-Ping injection combined with chemotherapy on the treatment of advanced non-small cell lung cancer [J]. Chin Clin Oncol 2009, 14:936-948.
18. Wang K, Guo ZX Xiaoaiping injection combining with NP regiment in the treatment of 56 patients with advanced lung cancer [J]. J Basic Clin Oncol 2009, 22:47-48.
19. Huang ZQ, Tan H, Wang CY, et al. Clinical research of combined Xiaoaiping injection with chemotherapy on advanced non-small cell lung cancer [J]. Chin Clin Oncol 2007, 12:97-99.
20. Hu CD Xiaoaiping in treatment of 33 patients with advanced stage malignant tumor [J]. China Med Heral 2001, 20:623.
21. Zhang MZ, He Z, Wu GY, et al. Effect of Xiaoaiping Injection on Ec-9706 cell line [J]. Lishizhen Med Mater Med Res 2008, 19:1182-1184.
22. Koumtebaye E, Su N, Hu WF, et al. Antitumor activity of Xiaoaiping injection on human gastric cancer SGC-7901 cells [J]. Chin J Nat Med 2012, 10:339-346.
23. Li D, Ouyang J, Li CP, et al. Preliminary study on effects of Xiaoaiping injection on NB4 cells [J]. China Biochem Pharmaceut J 2007, 28:247-250.
24. 1 arrest in senescent human fibroblasts [J]. Bioessays 1995, 17(6):537-543.
25. Cook SJ, Balmanno K, Garner A Regulation of cell cycle re-entry by growth, survival, and stress [J]. Biochem Soc Trans 2000, 28(2):233-240.
26. Correia I, Alonso-Monge R, Pla J MAPK cell-cycle regulation in Saccharocharomyces cerevisiae and Candida albicans [J]. Futre Mihrobiol 2012, 5(7):1125-1141.
27. Luo S, Lin L, Geoffrey AC, et al. Polyoxypregnanes from Marsdenia tenacissima [J]. Phytochemistry 1993, 34:1615-1620.
28. 1 cell-cycle control and cancer [J]. Nature 2004, 432(7015):298-306.
29. Vermeulen K, Van Bockstaele DR, Berneman ZN The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer [J]. Cell Prolif 2003, 36(3):131-149.
30. Shah MA, Schwartz GK Cyclin-dependent kinases as targets for cancer therapy [J]. Cancer Chemother Biol Response Modif 2003, 21:145-170.
31. Kennedy BK, Pennypacker JK RB and lamins in cell cycle regulation and aging [J]. Adv Exp Med Biol 2014, 773:127-142.
32. Duronio RJ, Xiong Y Signaling pathways that control cell proliferation [J]. Cold Spring Harb Perspect Biol 2013, 5(3):a008904.
33. Chambard JC, Lefloch R, Pouysségur J, et al. ERK implication in cell cycle regulation [J]. Biochim Biophys Acta 2007, 1773(8):1299-1310.
34. Mishra R Cell cycle-regulatory cyclins and their deregulation in oral cancer [J]. Oral Oncol 2013, 49(6):475-481.
35. Williams GH, Stoeber K The cell cycle and cancer [J]. J Pathol 2012, 226(2):352-364.
36. Shapiro GI Cyclin-dependent kinase pathways as targets for cancer treatment [J]. J Clin Oncol 2006, 24(11):1770-1783.
37. Tomoda K, Kato J Cdk inhibiting proteins [J]. Gan To Kagaku Ryoho 1997, 24(11):1407-1413.
38. Brader S, Eccles SA Phosphoinositide 3-kinase signaling pathways in tumor progression, invasion and angiogenesis [J]. Tumori 2004, 90(1):2-8.
39. Li W, Mei X, Tu YY Effects of tea polyphenols and their polymers on MAPK signaling pathways in cancer research [J]. Mini Rev Med Chem 2012, 12(2):120-126.
40. Zhang W, Liu H MAPK signal pathways in the regulation of cell proliferation in mammalian cells [J]. Cell Res 2002, 12(1):9-18.
41. Mebratu Y, Tesfaigzi Y How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? [J]. Cell Cycle 2009, 8(8):1168-1175.
42. Tournier C The 2 Faces of JNK Signaling in Cancer [J]. Genes Cancer 2013, 4(9-10):397-400.
43. Koul HK, Pal M, Koul S Role of p38 MAP kinase signal transduction in solid tumors [J]. Genes Cancer 2013, 4(9-10):342-359.
44. Grant S Cotargeting survival signaling pathways in cancer [J]. J Clin Invest 2008, 118(9):3003-3006.
45. Takada H Cell surface protein Ecm33 is involved in negative feedback regulation of MAP kinase signaling and development of the in vivo real-time monitoring of MAP kinase signaling [J]. Yakugaku Zasshi 2011, 131(8):1195-1200.
46. Caunt CJ, Keyse SM Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling [J]. FEBS J 2013, 280(2):489-504.
47. Gild ML, Bullock M, Robinson BG, et al. Multikinase inhibitors: a new option for the treatment of thyroid cancer [J]. Nat Rev Endocrinol 2011, 7(10):617-624.
48. Yang HP, Yue L, Jiang WW, et al. Diosgenin inhibits tumor necrosis factor-induced tissue factor activity and expression in THP-1 cells via down-regulation of the NF-κB, Akt, and MAPK signaling pathways [J]. Chin J Nat Med 2013, 11(6):608-615.
49. 1 phase [J]. Biochem J 1997, 326(Pt 1):61-68.